Reading a follicular lymphoma report: what pathology, PET and blood results can tell you

A pathology report names follicular lymphoma, a PET/CT describes several active nodes and a blood test marks LDH as high. It is easy to combine these findings into a conclusion that sounds more severe than the evidence supports. The reports do different jobs. Pathology identifies the disease, imaging describes its distribution, and laboratory tests help assess its effects on the body. Start by asking where and when each sample was obtained, then ask how the findings change the next decision.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

“Left cervical lymph-node excision,” “core biopsy of a retroperitoneal mass” and “bone marrow trephine” describe different samples. A whole node often provides a useful view of tissue architecture. A core can also be adequate, but small volume, crush artifact or necrosis may limit classification. An abnormal B-cell population found only in marrow does not always resolve the full lymphoma subtype; another site may be needed to answer that question.
Finding lymphoma in marrow commonly establishes stage IV disease. In adult classic follicular lymphoma, widespread distribution can still coexist with a long clinical course. The immediate management question depends on symptoms, organ effects, tumor burden and rate of change. A positive marrow finding alone does not establish that the patient has no useful treatment options or needs emergency chemotherapy.
Provide DICOM image series, full pathology and laboratory reports, and information on how to borrow slides or blocks. A written summary helps navigation but should not replace the originals. The receiving hematologist and pathologist can then decide whether existing evidence is sufficient. A well-defined question, such as whether grade 3A has been confirmed or whether one lesion requires biopsy, makes a second opinion more focused than a general request to “check everything.”

Quick answer

Full guide

Keep every page, including later additions. Morphology, immunohistochemistry, flow cytometry and FISH may be reported at different times. The first provisional conclusion may not contain the final interpretation, while an addendum may simply clarify one marker without changing the diagnosis. A specialist needs the complete record before deciding whether review or another biopsy is necessary. NCI lymphoma reference

Read the specimen description before counting positive stains

“Left cervical lymph-node excision,” “core biopsy of a retroperitoneal mass” and “bone marrow trephine” describe different samples. A whole node often provides a useful view of tissue architecture. A core can also be adequate, but small volume, crush artifact or necrosis may limit classification. An abnormal B-cell population found only in marrow does not always resolve the full lymphoma subtype; another site may be needed to answer that question.

Note whether the sample was taken before or after steroids, chemotherapy or antibody treatment. Therapy can affect the appearance of tissue or the expression of some markers. If the report says “limited material” or recommends further sampling, retain that statement in any translation. It is a real diagnostic limitation. The clinician should explain what additional tissue could establish and how that answer would change care. NICE biopsy recommendations

Follicular architecture, grade and stage are different descriptions

The word follicular describes a pattern of cells within tissue. It does not mean that the lymphoma is one neatly enclosed lump that is necessarily cured by removing it. A report can describe both follicular and diffuse areas, which the pathologist interprets with the cell types present. The word “diffuse” on its own does not prove transformation to diffuse large B-cell lymphoma.

Older reports commonly use grades 1, 2, 3A and 3B. Many adult classic cases are approached as an indolent lymphoma, while grade 3A may require particular attention to pathology and clinical behavior. Disease historically called grade 3B needs reconciliation with current terminology and generally enters an aggressive lymphoma discussion. The specialist should translate the complete diagnosis into a treatment implication rather than allowing the numerical grade to make the decision alone.

Stage I through IV instead describes the distribution of disease in the body. Grade 3 is not stage III. Pediatric-type follicular lymphoma, duodenal-type disease and primary cutaneous follicle center lymphoma also require distinct interpretation. A younger age or an intestinal location is a clue, not permission to relabel the disease without supporting evidence. Ask the team to write the complete diagnostic name being used. ESMO classification and management guidance

Interpret CD20, CD10, BCL2 and Ki-67 as a panel

CD20 and other B-cell markers help establish lineage and may be relevant to an anti-CD20 treatment discussion. CD10 and BCL6 support germinal-center differentiation in the appropriate setting. BCL2 staining provides another piece of the diagnostic pattern. A negative BCL2 result does not automatically exclude every follicular lymphoma entity, and a positive stain does not mean the disease is at a later stage. Each plus sign is not an additional separate diagnosis.

Ki-67 estimates proliferative activity in the tissue examined. A report may give a range or identify a hotspot with higher staining than the rest of the sample. Sampling location and the method of assessment influence that number. It cannot independently predict an individual's lifespan or determine a universal threshold for intensive chemotherapy. A mismatch between Ki-67, cell appearance and clinical behavior may justify expert review or additional tissue.

FISH can show a rearrangement involving BCL2 or another gene. Such a finding can support the diagnostic interpretation, but it does not automatically establish that a particular tablet is indicated. Molecular evidence, drug efficacy, regulatory authorization and hospital supply are separate questions. Older documents may also describe drugs whose safety or availability has since changed. German diagnostic guideline

PET numbers need anatomical and clinical context

SUV is one way to quantify uptake of the PET tracer. Preparation, blood glucose, scan timing and technical factors can affect it. The result should be read with the lesion's location, appearance and comparison with previous imaging. Inflammation and infection can also be active. An unusually active or fast-changing site may deserve biopsy, but the scan cannot itself establish histological transformation.

Size change and metabolic change provide related but distinct information. A treated area may leave residual tissue even when its metabolic activity has improved substantially. Another area may retain uptake that needs follow-up or biopsy if the result would alter management. “Possibly inflammatory” is not equivalent to proven residual lymphoma. Similarly, “cannot exclude” states uncertainty rather than confirmation.

Deauville scoring compares lesion uptake with reference tissues and is interpreted within an appropriate response framework. The meaning depends on treatment timing and the clinical question. A score should not trigger an unsupervised drug change. At the consultation, ask the doctor to identify the principal target lesions, explain their change from baseline and point out any site that remains uncertain. This is more useful than comparing isolated numbers from unrelated scans.

Marrow involvement and low counts do not say the same thing

Finding lymphoma in marrow commonly establishes stage IV disease. In adult classic follicular lymphoma, widespread distribution can still coexist with a long clinical course. The immediate management question depends on symptoms, organ effects, tumor burden and rate of change. A positive marrow finding alone does not establish that the patient has no useful treatment options or needs emergency chemotherapy.

Low hemoglobin can have several causes, including marrow disease, iron deficiency, kidney dysfunction or bleeding. Platelet changes can relate to splenic effects, medicines or infection. Put serial blood counts in date order and retain units, especially when documents come from different countries. A clinician can then distinguish a stable longstanding abnormality from a new or accelerating decline.

LDH should be interpreted against the reporting laboratory's reference range. A mild isolated increase differs from a substantial persistent rise, and a hemolyzed sample or another illness can affect the result. FLIPI combines selected clinical findings for a population-level prognosis discussion. It does not replace diagnostic reasoning or supply an automatic treatment trigger in an asymptomatic person. NCI patient information

Response, progression and transformation require different evidence

Response describes how lymphoma changes with treatment. Complete and partial responses are useful assessments, but complete remission of previously widespread follicular lymphoma is not a promise that disease can never return. Apparent progression may involve enlarging lesions or new sites; infection and other competing explanations still need consideration. If the images and the patient's recovery seem inconsistent, additional confirmation may be preferable to immediately choosing another treatment.

Transformation means that the histology has changed to a more aggressive lymphoma. A quickly growing mass, new marked systemic symptoms or one lesion behaving differently from the others can prompt an investigation. Representative tissue is needed when feasible. Early progression is not automatically transformation. POD24 is a research and clinical concept with a specified starting point and treatment context, so it should not be assigned merely by counting months since diagnosis. Original early-progression study

Research reports also distinguish progression-free survival from overall survival. A treatment can delay a progression event without a demonstrated overall survival advantage. For example, this distinction is relevant when reading evidence about antibody maintenance. If a clinician cites a gain in disease-control time, ask which patients and preceding treatment were included in the study and whether that situation matches the present case. PRIMA long-term report

Resolve disagreements by finding the source of the difference

Two reports may sound contradictory because they use different classification terms, examine different material or describe disease at different times. Ask each team to identify the actual basis of the disagreement: a specific section of tissue, an imaging site or missing clinical information. That can show whether another pathology opinion, a new biopsy or simply clarification of terminology is needed.

The wording of uncertainty must survive translation. “Suspicious for,” “consistent with” and “cannot exclude” carry different implications in context. A summary that converts every phrase into “confirmed” can push treatment in the wrong direction. The same applies to laboratory language: “not tested” is not a negative result. Retain the original report alongside any translated version and have clinically meaningful differences checked.

An organized record can use one row per date, with the specimen or scan, the clinical situation at the time and the main unresolved question. Mark whether the person was on treatment, had just completed therapy or was attending follow-up. Include dates of growth factors, infection and recent procedures where these could affect scan interpretation. This keeps the doctor from comparing results that were obtained under very different conditions.

Bring a complete record to a China second opinion

Provide DICOM image series, full pathology and laboratory reports, and information on how to borrow slides or blocks. A written summary helps navigation but should not replace the originals. The receiving hematologist and pathologist can then decide whether existing evidence is sufficient. A well-defined question, such as whether grade 3A has been confirmed or whether one lesion requires biopsy, makes a second opinion more focused than a general request to “check everything.”

Ask a China institution to separate RMB charges for slide review, additional stains, FISH, a new biopsy and imaging interpretation. A report-review consultation and a complete repeat diagnostic workup are different services. No verified international self-pay quotation is available here, so a universal numeric price would not be reliable. Clarify laboratory turnaround and whether extra material could be needed before fixing travel dates or the next treatment cycle.

Leave the results visit with three written elements: what is established, what remains uncertain and what action will resolve the uncertainty. Stable disease may allow time for an addendum. Rapidly worsening breathlessness, substantial bleeding, persistent high fever or new confusion calls for local urgent evaluation. The report contributes evidence, while the patient's current condition determines how quickly that evidence must be acted on. NICE patient treatment pathway